Multiple cutaneous angiosarcomas after breast conserving surgery and bilateral adjuvant radiotherapy: an unusual case and review of the literature. by Meattini, Icro et al.
Case Report
Multiple Cutaneous Angiosarcomas after Breast Conserving
Surgery and Bilateral Adjuvant Radiotherapy: An Unusual Case
and Review of the Literature
Icro Meattini,1 Raffaella Santi,2 Daniele Scartoni,1 Irene Giacomelli,1
Carla De Luca Cardillo,1 Vieri Scotti,1 Donato Casella,3 Roberta Simoncini,3
Lorenzo Orzalesi,3 Jacopo Nori,4 Milena Paglierani,2 and Lorenzo Livi1
1 Department of Radiation-Oncology, University of Florence, Largo G.A. Brambilla 3, 50134 Florence, Italy
2 Division of Pathological Anatomy, University of Florence, Largo G.A. Brambilla 3, 50134 Florence, Italy
3 Department of Surgery, University of Florence, Largo G.A. Brambilla 3, 50134 Florence, Italy
4Diagnostic Senology Unit, University of Florence, Largo G.A. Brambilla 3, 50134 Florence, Italy
Correspondence should be addressed to Icro Meattini; icro.meattini@unifi.it
Received 7 January 2014; Accepted 2 February 2014; Published 5 March 2014
Academic Editors: S. Aksoy, J. M. Buchanich, and L. Lu
Copyright © 2014 Icro Meattini et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Breast angiosarcomas (BAs) are rare but serious events that may arise after radiation exposure. Disease outcome is poor, with high
risk of local and distant failure. Recurrences are frequent also after resection with negative margins. The spectrum of vascular
proliferations associated with radiotherapy in the setting of breast cancer has expanded, including radiation-associated atypical
vascular lesions (AVLs) of the breast skin as a rare, but well-recognized, entity. Although pursuing a benign behavior, AVLs have
been regarded as possible precursors of postradiation BAs. We report an unusual case of a 71-year-old woman affected by well-
differentiated bilateral cutaneous BA, diagnosed 1.9 years after adjuvant RT for synchronous bilateral breast cancer. Whole-life
clinical followup is of crucial importance in breast cancer patients.
1. Introduction
Angiosarcomas (ASs) are rare malignant tumors that arise
from endothelial cells lining vascular channels [1, 2]. They
account for less than 1% of all soft tissue sarcomas and
occur in all organs of the body. Approximately 8% of ASs
arise in the breast [3]. Primary breast angiosarcomas (BAs)
most commonly affect women aged 20 to 40 years without a
recognized associated factor [4].
Secondary BAs are usually found in older women at
the site of radiotherapy (RT) for breast cancer (BC). They
typically involve the dermis and present with skin changes
that can easily bemisinterpreted even with benign conditions
such infection [5].
Neoplastic events attributed to RT in the context of BC
are rare. Such occurrences are largely restricted to possible
secondary lung and BC, osteosarcomas, malignant fibrous
histiocytomas, and fibrosarcomas [5–8].
Postradiation BAs are defined by three characteristics:
location in the field of radiation, latency of years after RT, and
histologic distinction from the primary neoplasm [9]. The
latency period, or interval between RT and the diagnosis of
BA, ranges from 3 to 12 years, with most tumors occurring
within 6 years after RT [10].
In recent years, the spectrum of vascular proliferations
associated with RT in the setting of BC has expanded, includ-
ing radiation-associated atypical vascular lesions (AVLs) of
the breast skin as a rare, but well-recognized, entity [9, 11].
Since clinic and histologic overlapwithwell-differentiated BA
is likely, AVLs represent a diagnostic and therapeutic chal-
lenge. Moreover, although pursuing a benign behavior, AVLs
have been regarded as possible precursors of postradiation
BAs [12].
We report an unusual case of a 71-year-old woman
affected by well-differentiated bilateral cutaneous BAs,
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(a) (b)
Figure 1: Reexcision of postradiation AVL of the breast skin one month after initial biopsy. Capillary vessels were lined by inconspicuous
endothelial cells and randomly arranged throughout the dermis ((a);H&E,×10). At the periphery of the lesion, a small focus displayed vascular
structures with frank cytological atypia andmitotic figures, consistent with well-differentiated post-RT cutaneous BA (inset; H&E,×40).MYC
amplification at FISH analysis strongly supported the diagnosis of AS versus AVL (b). In order to detect copy number abnormalities of MYC
oncogene (located at 8q24,12-q24.13), the LSI C-MYC SpectrumOrange Probe (Abbott Molecular Inc., Abbott Park, IL, USA) was used. The
fluorescent signals were evaluated under an epifluorescence microscope (DMRD, Leica Mikrosystems Vertrieb GmbH, Germany), using a
HBO 100Wmercury arc lamp and the appropriate single band filters (orange and blue) for the two fluorescence signals.
diagnosed 1.9 years after adjuvant RT for synchronous
bilateral BC.
2. Case Report
In October 2009, due to a swelling in the central superior
quadrant of the right breast, discovered by self-palpation, the
patient underwent mammography showing a 20mm opacity
diagnosed as invasive BC at biopsy.The patient was subjected
to wide excision of the lesion, biopsy of two sentinel lymph
nodes, and contralateral reconstructive surgery. Histological
examination showed amultifocal invasive lobular BC (classic
and alveolar type), nuclear grade 2 with pathologic staging
pT1cN0. Estrogen receptors and progesterone receptors were
positive in 90% and 70% of neoplastic cells, respectively; Ki-
67 proliferative indexwas<5% andHER2 status was negative.
On the left breast, pathology showed a ductal carcinoma
in situ (solid and cribriform type), nuclear grade 2. Estrogen
receptors and progesterone receptors were positive in 100%
and 80% of neoplastic cells, respectively. Postoperative clin-
icoradiologic staging was negative. Hormonal therapy with
letrozole was started.
Both breasts were irradiated. Right breast received a total
dose of 60Gy (50Gy on the whole breast plus a boost of
10Gy on the tumor bed) and left breast received a total dose
of 50Gy, with conventional fractions of 2Gy/day. Computed
tomography-based simulation (Big Bore Oncology, Philips,
Andover, MA, USA) was performed; a three-dimensional RT
planning Pinnacle system (Philips Medical System, Bothell,
WA, USA) was used. Both breasts were irradiated with two
tangential photon beams while boost was performed with
electron beams with energy of 12MeV. Acute side effects were
scored according to the Common Toxicity Criteria Adverse
Events (CTCAE, version 4).The treatment was well tolerated,
with only bilateral breast erythema G1 and asthenia G1.
Figure 2: Surgical specimendisplayingwell-differentiatedASwhich
arose in AVL (H&E, ×10; inset, H&E, ×40).
Regular follow-up visits were performed with annual
bilateral mammography and breast ultrasound. In March
2012, at 1.9 years from RT, a small discolored area around
the right surgical scar was detected; biopsy showed a
radiation-associated AVL. Subsequently, the patient under-
went wide excision with histologic diagnosis of cutaneous
well-differentiated BA, arising as a small focus on a radiation-
associated AVL (Figure 1(a)). Molecular analysis performed
by fluorescence in situ hybridization (FISH) demonstrated
the presence ofMYC [13] amplification (Figure 1(b)). Surgical
margins were negative.
On January 2013, at 2.7 years from RT, a lesion appeared
on the right breast; therefore patient underwent bilateral
mastectomy. The final histology report showed bilateral
mild differentiated cutaneous BAs in both breasts, diffusely
infiltrating adipose tissue, and dermohypodermic stroma,
with bilateral nipple-areola complex involvement (Figure 2).
Patient showed metastatic disease at restaging instru-
mental tests (multiple lung metastases) and started systemic
therapy. At time of writing, 23 months since diagnosis of
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first BA, patient showed partial response to chemotherapy
(endovenous docetaxel and gemcitabine, 6 cycles) and started
hormonal therapy (letrozole).
3. Discussion
Thedevelopment of malignant tumors after exposure to radi-
ation is a well-recognized event. As a serious complication
following therapeutic RT, the development of a sarcoma is a
rare event [14]. The first reported case of BA arising within
the skin overlying an irradiated breast was published in 1981
[15]. According to a large overview, BAs make up 15% of RT-
related sarcomas [16].
Despite the apparent correlation between reports of
secondary BAs and the increasing use of breast-conserving
therapy, a true etiologic effect from RT has been difficult to
establish. Although the preserved breast is the most common
site of soft tissue sarcoma in patients receiving RT for BC,
secondary BAs may also occur out of field [17].
Lymphedema has been implicated as a potential causative
factor in the development of BA [18]. It has been suggested
that the proliferation of lymphatic channels observed in
patients with chronic lymphedema is mediated by growth
factors that enhance the process of malignant transformation
[4]. Chronic lymphedema may also produce a privileged
site with reduced immunologic surveillance [1, 19]. Further-
more, exposure to RT may compound the risk of malignant
transformation by its mutagenic effect and by causing lym-
phosclerosis, which exacerbates the obstruction associated
with lymphadenectomy.
Compared to sporadic BAs, which usually arise in the
parenchyma, RT-related BA is usually cutaneous; clinically,
it presents as an erythematous plaque, patch, or nodules,
often with edema, and evokes a differential diagnosis that
includes inflammatory carcinoma or an infectious etiology
[20]. Overall the prognosis for patients with RT-associated
BA is poor, with high rates of local and distant recurrence
[9, 17]. Vorburger et al. [21] showed a median disease-free
survival (DFS) for patients with primary BAs of 6.5 years and
a 5-year DFS rate of 56%.
Despite the high probability of local disease recurrence,
the mainstay of treatment is a simple mastectomy or a
wide local excision. A review reported published cases with
at least 1 year of followup and showed that around 70%
of patients developed BA recurrences within 1 year from
surgery (Table 1). Evenwith negativemargins through radical
salvage surgery by simplemastectomy, radicalmastectomy, or
chest wall resections, additional local tumor recurrences are
common [18].
Our unusual case is an example of how skin BAs after RT,
although rare, are increasing phenomena. This case differs
from the classic postradiation BA presentation reported in
the literature. There are no risk factors which may explain
this relatively short latency period (1.9 years); there is also no
evidence of lymphedema.
Our report emphasizes the difficulty in differentiating
well-differentiated BAs from AVLs on both the clinic and
histologic findings [14]. Moreover, since AVLs are known
to have a shorter interval from RT as compared to AS,
postradiationAVLwas the expected histological diagnosis. In
the context of postradiation, histopathologic characteristics
of vascular proliferations should be interpreted with extreme
caution. As in this case, anastomosing small vessels exhibiting
marked endothelial atypia and the presence of mitotic figures
should favor the diagnosis of post-RT well-differentiated AS.
In the differential diagnosis between these entities additional
help comes from FISH analysis demonstrating MYC amplifi-
cation, which is present in post-RT ASs but not in AVLs [13].
4. Conclusions
Postradiation BAs represent a rare but serious occurrence.
Latency between RT and BA diagnosis may vary and may
be influenced by several predisposing and treatment factors.
Recurrences are frequent also after resection with negative
surgical margins. Atypical vascular lesions require careful
evaluation to rule out BAs. Clinical and instrumental fol-
lowup is of crucial importance for these patients.
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